By Fineline Cube 
BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced its financial results and business progress for the second quarter of 2025 on August 6, 2025. The company reported total revenue of $1.3 billion, marking a 42% year-on-year increase. This growth was primarily driven by the sales of Brukinsa (zanubrutinib) in the United States and Europe, with global Brukinsa revenue reaching $950 million, up 49% year-on-year.
Product Revenue Growth
In Q2 2025, the company’s product revenue was $1.3 billion, compared to $921 million in the same period last year. The increase was mainly attributed to the growth of Brukinsa sales. The United States remains the largest market, with product revenue reaching $685 million, up from $479 million in the previous year’s quarter. Sales of products licensed from Amgen and Tislelizumab also contributed to the revenue growth.
Half-Year Performance
For the first half of 2025, the company’s revenue was 17.518 billion yuan (RMB), a 46% year-on-year increase. Product revenue was 17.360 billion yuan, up 45.8%. Global sales of Brukinsa totaled 12.527 billion yuan, an increase of 56.2%. U.S. sales were 8.958 billion yuan, up 51.7%, while European sales reached 1.918 billion yuan, up 81.4%. Sales in China were 1.192 billion yuan, up 36.5%.
Tislelizumab Performance
Sales of Tislelizumab totaled 2.643 billion yuan in the first half of 2025, an increase of 20.6%. The growth was primarily due to new patient demand from the inclusion of newly approved indications in China’s national medical insurance system and an increase in the number of hospitals carrying the drug. Tislelizumab has secured a leading market share in the PD-1 market in China.-Fineline Info & Tech